Ozempic, Wegovy and Zepbound While Breastfeeding: What the Labels Say

Ozempic’s label does not forbid breastfeeding. It notes that no data exist on semaglutide in human milk, then leaves your prescriber to balance what breastfeeding gives your baby against how much you need the drug.^[1] The answer changes with the product. The semaglutide tablets (Rybelsus, Ozempic tablets and the Wegovy pill) say breastfeeding is not recommended, because an ingredient in the tablet reaches human milk.^[2][3] Foundayo says it is not recommended for nursing women.^[7] Zepbound and Mounjaro are the only ones with a human milk study on the label, and tirzepatide was undetectable in almost every sample.^[4][5] Which of them, if any, suits your situation is something to settle with your clinician.

The short answer, drug by drug

The pattern does not follow the molecule. Semaglutide gets one answer as an injection and the opposite answer as a tablet. The two tablets that advise against breastfeeding do so for different reasons: the semaglutide tablets because of an ingredient added to them, and Foundayo because of how the drug itself behaved in animal milk. Name the exact product, not just the drug, when you ask about breastfeeding.

Ozempic and Wegovy injections: what the label says

Ozempic’s section 8.2 is short. This is its risk summary in full:

“There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. Semaglutide was present in the milk of lactating rats, however, due to species-specific differences in lactation physiology, the clinical relevance of these data are not clear (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for OZEMPIC and any potential adverse effects on the breastfed infant from OZEMPIC or from the underlying maternal condition.”^[1]

— Ozempic prescribing information, §8.2 Lactation

In those rats, semaglutide in milk ran 3 to 12 times lower than in the mother’s blood.^[1] The Wegovy label applies the same weighing to the injection and adds one line that matters for the next section: “WEGOVY subcutaneous injection does not contain the SNAC metabolites.”^[2] Neither label tells you to stop breastfeeding or to avoid the drug. They leave it to the prescriber.

The Wegovy pill and Rybelsus: why the tablets say no

Semaglutide is a protein-like molecule that the gut normally breaks down, so the tablets include an absorption enhancer called salcaprozate sodium, or SNAC. That ingredient drives the lactation advice, not the semaglutide. The Wegovy label puts it this way:

“Data from a clinical lactation study with semaglutide oral tablet formulation reported semaglutide concentrations below the lower limit of quantification in human milk. However, SNAC and/or its metabolites are present in human milk. Since the activity of enzymes involved in SNAC clearance may be lower in infants compared to adults, higher SNAC plasma levels may occur in neonates and infants. Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC, and because there are alternative formulations of semaglutide that do not contain SNAC that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with WEGOVY tablets.”^[2]

— Wegovy prescribing information, §8.2 Lactation (tablets)

The Rybelsus and Ozempic tablets label uses nearly the same words. The only change is that it points to “alternative semaglutide products” rather than “alternative formulations of semaglutide”.^[3] So the label itself names the way around the problem: if a semaglutide product is right for you while nursing, it would be an injection. LactMed puts it more directly: “Only injectable forms of semaglutide should be used during breastfeeding.”^[8] The tablet’s other warnings are in Wegovy pill side effects.

Zepbound and Mounjaro: the only label with a human milk study

Both tirzepatide labels report the same study, word for word:

“Following subcutaneous administration of a single 5 mg dose to 11 healthy lactating adult females, the concentration of tirzepatide in breast milk was found to be undetectable (limit of detection in breast milk 4 ng/mL) in 164/171 samples assayed. The cumulative amount of tirzepatide detected in the remaining 7 breast milk samples over the 28-day sampling window was equivalent to less than 0.02% of the maternal administered dose, with the last measurable concentrations occurring 5 days post-dose.”^[4][5]

— Zepbound and Mounjaro prescribing information, §8.2 Lactation (Data)

That is a reassuring transfer figure. Still, look at what was tested: one dose, 5 mg, in 11 women. Zepbound’s maintenance doses run to 10 and 15 mg, and people take them every week.^[4] LactMed makes the same point: the study “does not account for accumulation that would occur during typical use, so the amounts in milk at steady-state are probably greater than indicated.”^[9] Both labels also say plainly that there are no data on how tirzepatide affects a breastfed infant or milk production, and both fall back on the same benefit-versus-need weighing as Ozempic.^[4][5]

Saxenda and Foundayo

Saxenda (liraglutide) has no human milk data at all. In rats, liraglutide appeared in milk unchanged at about half the mother’s blood level.^[6] The label uses the same weighing, and its patient guide puts it in one line: “You and your healthcare provider should decide if you will use SAXENDA or breastfeed.”^[6]

Foundayo (orforglipron), Lilly’s daily pill, is the firmest of the group. In rats it reached milk at concentrations three times higher than in plasma. The label then reasons: “When a drug is present in animal milk, it is likely that the drug will be present in human milk. FOUNDAYO is not recommended for nursing women.”^[7] The usual benefit-weighing sentence follows straight after, so the label is not an absolute ban. It is still the only GLP-1 label that advises against breastfeeding because of the drug itself. LactMed has no human information either and says “an alternate drug may be preferred, especially while nursing a newborn or preterm infant.”^[11]

What LactMed says

LactMed, published by the National Institute of Child Health and Human Development, is the federal database on drugs in breastfeeding. Its 2026 summaries for the three most-used molecules, quoted in full:

Semaglutide: “Semaglutide was not detectable in the milk of mothers taking the drug subcutaneously. Their breastfed infants experienced no adverse effects. Some brands of oral semaglutide, such as Rybelsus, contain the absorption enhancer salcaprozate sodium, which may enter milk and accumulate in infants. Only injectable forms of semaglutide should be used during breastfeeding. Some experts recommend closely monitoring of infant growth and developmental milestones and the nutritional status of the lactating woman.”^[8]

— LactMed, Semaglutide, revised August 2026

Tirzepatide: “Tirzepatide is usually undetectable in breastmilk with subcutaneous doses of up to 5 mg. Furthermore, absorption by the infant is unlikely because it is probably partially destroyed in the infant’s gastrointestinal tract and poorly absorbed orally. If a mother requires tirzepatide, it is not a reason to discontinue breastfeeding. Until more data become available, tirzepatide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Some experts recommend closely monitoring of infant growth and developmental milestones and the nutritional status of the lactating woman.”^[9]

— LactMed, Tirzepatide, revised August 2026

Liraglutide: “No information is available on the use of liraglutide during breastfeeding. Because liraglutide is a large peptide molecule with a molecular weight of 3751 daltons, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant’s gastrointestinal tract. Until more data become available, liraglutide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Some experts recommend closely monitoring of infant growth and developmental milestones and the nutritional status of the lactating woman.”^[10]

— LactMed, Liraglutide, revised August 2026

Two points stand out. The LactMed summaries are, if anything, a little more permissive than the labels for the injectables. And all three single out newborns and preterm babies, plus the mother’s own nutrition. That last point is the one the labels do not raise.

The human milk studies, and how small they are

The whole human evidence base fits in a short list:

• Semaglutide injection: 8 mothers. A 2024 study measured milk from eight women on weekly injections at 0, 12 and 24 hours after a dose. Semaglutide was not detected in any sample, with a detection limit of 1.7 ng/mL. Using the assay’s limit as a worst case, the authors put the most a baby could receive at 1.26% of the mother’s weight-adjusted dose, well under the usual 10% threshold.^[12] LactMed adds that the mothers took 0.25 to 1 mg a week, their babies were 4 to 23 months old and mixed fed, and the mothers reported normal growth and development.^[8] No newborns were studied, and none of the doses went above 1 mg.
• Semaglutide tablets: a manufacturer study on the label, with semaglutide below quantification and SNAC present. The label does not say how many women took part.^[2][3]
• Tirzepatide: 11 women, one 5 mg dose, the label study above.^[4] Plus a preprint of 5 women on 2.5 to 5 mg weekly, cited by LactMed, in which no sample reached the 2.38 mcg/L quantification limit and no mother reported effects in her baby attributable to the drug. It had not been peer reviewed when LactMed cited it.^[9]
• Liraglutide and orforglipron: none.^[10][11]

Counting only the studies that state their size, that is 24 women for the whole class, and no study has measured drug levels in a breastfed baby’s blood.^[8][9] Reviews from 2026 agree. One systematic review of 36 studies on GLP-1 use around pregnancy and lactation found lactation data “sparse”, with only the semaglutide study above.^[15] A review of diabetes drugs in breastmilk found that only 5 of 20 drugs, semaglutide among them, had any human transfer data, and that only 4.4% of guideline recommendations on using these drugs while breastfeeding were based on clinical evidence.^[14] A 2026 international consensus group went the other way and opened by calling breastfeeding on incretin-based medications contraindicated. Its review found just one study on lactation.^[13] So the experts do not agree, and the reason is that there is so little data.

Milk supply: no data either way

This is the question nursing parents ask most often, and the honest answer is short. Every label in the table says the same thing about milk production: there are no data on how the drug affects it.^{[1][2][4][6][7]} Under “Effects on Lactation and Breastmilk”, LactMed’s semaglutide, tirzepatide and liraglutide entries each read: “Relevant published information was not found as of the revision date.”^[8][9][10]

So there is no study showing these drugs reduce supply, and none showing they don’t. Claims either way online are guesses. What the sources do flag is indirect: these drugs cut appetite, and both LactMed and the semaglutide milk study authors name the lactating mother’s own nutrition as an open question.^[8][12] If you notice your supply changing, or your baby’s feeding or weight gain, take that to your prescriber and your baby’s clinician. Do not wait for a study to settle it.

Postpartum birth control and tirzepatide

Postpartum is also when many people start or restart contraception, and this is where tirzepatide has a labeled interaction. Zepbound and Mounjaro both say:

“Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation.”^[4][5]

— Zepbound and Mounjaro prescribing information, §8.3 Contraception

The wording covers oral hormonal contraceptives in general, not one kind of pill. Foundayo carries the same advice over 30-day windows.^[7] The semaglutide labels do not carry this advisory. The mechanism, and what each label actually tested, are in GLP-1s and hormonal birth control.

If you start a GLP-1 after delivery while relying on a pill, settle the method with your prescriber first. Fertility can come back before your cycles feel regular, and the advisory resets with every dose step. The pregnancy, fertility and contraception cheat sheet sums up these timing rules on one page.

When after delivery: what the evidence covers

No GLP-1 label names a postpartum start date. The only timing rules on the labels are about the pregnancy itself and the lactation advice above. Prescribing has moved ahead of the evidence anyway. A 2026 analysis of U.S. deliveries found semaglutide and tirzepatide prescriptions in the year after delivery rose from 0.3 to 14.6 per 1,000 deliveries between 2019 and 2024, and the authors called for safety data to catch up.^[16]

There is some trial evidence for use after pregnancy. In a randomized trial of 153 women with overweight or obesity who had gestational diabetes within the previous 12 months, adding liraglutide 1.8 mg to metformin led to more weight loss and better insulin sensitivity than metformin alone. Only 47% finished the 84 weeks, and the published summary does not report whether the women were breastfeeding.^[17] It shows the drug can work after delivery. It does not show it is safe for a nursing baby.

In practice, the timing question is several questions at once: whether you are breastfeeding, how old the baby is (the sources single out newborns and preterm babies), which product, what it is treating, and what the alternatives are. Type 2 diabetes after pregnancy is a different calculation from postpartum weight loss. LactMed lists insulin and metformin among the alternatives to consider for diabetes.^[8] Bring all of that to your prescriber, and ideally to your baby’s clinician as well. The drug pages for Ozempic and Zepbound cover doses and the rest of each label.

Questions to take to the appointment

1. Is this an injection or a tablet? For semaglutide, the labels give opposite answers by form.
2. How old is my baby, and were they born early? LactMed’s cautions are strongest for newborns and preterm infants.
3. What is the drug treating, and what are the alternatives while I nurse?
4. What should we watch? LactMed mentions the baby’s growth and milestones and the mother’s own nutrition.
5. Am I on a pill for contraception? With tirzepatide or Foundayo, the label calls for a backup method at the start and after each dose increase.